Omeros VP finance David Borges sells $419,000 in shares

David Borges, Vice President of Finance and Chief Administrative Officer at Omeros Corp, sold 20,000 shares of the company's stock on September 22 and 23, 2026. The shares were sold at a rate of $20.95 per share, amounting to $419,000. This sale was part of a pre-planned series of transactions outlined in a Rule 10b5-1 trading plan Borges established on February 10, 2026.

On the same days, Borges also bought back 20,000 shares using stock options, spending a total of $190,150 on these purchases. The options were exercised at various prices, with the lowest being $2.94 per share and the highest at $15.58 per share. Specific exercises included 5,000 shares at $3.93 on September 22 and another 5,000 shares at $2.94 on the same day.

On September 23, 10,000 shares were bought using options priced at $15.58. After these transactions, Borges holds no additional common stock in Omeros. Meanwhile, Omeros reported strong second-quarter earnings, beating market forecasts with $0.02 per share in adjusted earnings and $28.5 million in revenue - a sharp contrast to the expected $12.67 million.

The company's success was largely credited to the rapid launch and approval of their new drug, Yartemlea. Following the positive results, Cantor Fitzgerald upgraded Omeros' stock rating to "Overweight" from "Neutral" and set a price target of $22.00, highlighting the impressive performance of Yartemlea as a major factor.